Breaking News, Collaborations & Alliances

Epicrispr Biotechnologies and Forge Biologics Announce AAV Development and Manufacturing Pact

Epicrispr’s investigational gene therapy, EPI-321, is a treatment for facioscapulohumeral muscular dystrophy.

Author Image

By: Patrick Lavery

Content Marketing Editor

Epicrispr Biotechnologies and Forge Biologics are beginning a strategic partnership for development and manufacturing of an adeno-associated virus (AAV) therapy. The investigational AAV gene therapy, Epicrispr’s EPI-321, intends to treat facioscapulohumeral muscular dystrophy (FSHD). According to the Muscular Dystrophy Association, FSHD most affects the muscles of the face, shoulder blades, and upper arms. EPI-321’s design silences aberrant expression of double homeobox 4, or DUX4, in skel...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters